RankAlpha logo
Back to Rankings

PHIO

PhioB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The post-earnings company update improved the operating narrative versus the prior baseline: PH-762 dose escalation is complete, management highlighted favorable safety/pathology data, FDA interaction is targeted in Q2 2026, and longer-horizon toxicology and cGMP supply work is now explicitly part of the advancement path.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Cash declined to about $17.0 million by March 31, 2026, and the April 2026 ATM creates additional dilution risk even if it extends flexibility.
Momentum
87
Value
41
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.15 · Bull $2.00 · Bear $0.45
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $14.00
Why
Momentum87 · Δ7d -
Value41 · Δ7d +0.1
Sentiment52 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
87
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
52
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 86.7 / Value 41.1 / Sentiment 51.7

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$13.13M
Beta
0.93
Shares Out
10.76M
P/E (TTM) · Derived
-0.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.66
Rev YoY
-
EPS YoY
+71.6%
Gross Margin
-
Op Margin
-
Net Debt
-$5.38M
Current Ratio
6.90
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology